Core Viewpoint - The company has initiated the sales of its rabies immune globulin product, which is now listed on drug procurement platforms in certain provinces, marking a significant step in its market presence [1] Group 1: Product Development and Sales - The rabies immune globulin product is an existing product that had previously not been sold on a large scale due to distribution channel issues and allergic reactions [1] - Continuous process improvement research is being conducted on the product, with production planned for the second half of 2024 and ongoing efforts to list the product on procurement platforms across provinces in 2025 [1] Group 2: Market Position and Regulatory Status - The rabies immune globulin has a specific role in neutralizing the rabies virus and is used for preventive injections in individuals severely bitten by suspected rabid animals [1] - Currently, the company is the only manufacturer and seller of rabies immune globulin in the market [1] - The product is included in the National Essential Medicines List and the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List [1]
赛伦生物:抗狂犬病血清产品已挂网销售